Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody-远泰生物

提醒成功

QQ登录

微信登录

同意并阅读使用条款和隐私策略

账号密码登录

微信/QQ登录

没有账号？立即注册

搜索

抗体销售咨询健康评估咨询 mRNA-LNP咨询

0731-88388787

首页 > 产品中心 > 产品详情

产品规范
Type	In Vivo - Reseach Grade Antibody
Host	CHO cells
catalog#	B00051
Application	Flow cytometry, animal model study
Aliases	Lymphocyte Activation Gene 3, LAG3, CD223, Cluster of Differentiation 223
Size/Concentration	1mg/5mg/20mg
Isotype	Human IgG4 kappa
Storage	Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Human LAG-3
Formulation	PBS, pH 7.4

Description
What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3–blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti–PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti–PD-1 monotherapy.

Description

What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3–blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti–PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti–PD-1 monotherapy.

Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody B00051

规格：

1mg
5mg
20mg

数量：

说明书：

¥1300

~~¥1300~~

加入购物车

立即购买

咨询

ProMab Biotechnologies, Inc.

联系方式

CONTACT

联系电话:

0731-88388787
公司邮箱:

sales@promab.cn
公司地址:

湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼

官方微信

产品中心

Product

技术服务

service

客户留言

message